Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 29, 2005

View Archived Issues

Second closing of Cellerant Therapeutics' Series B financing

NAP and ADNF-9 exert neuroprotective effects via PARP-1 activation and polyADP-ribosylation

IFN-alpha-XL shows promise in the management of chronic hepatitis C

First data on the antitumor efficacy of artesunate in metastatic uveal melanoma

Cubist submits Cubicin sNDA filing, requests priority review

Glenmark seeks clearance for phase I trials of DPP-IV inhibitor GRC-8200

International Medical Innovations changes name to PreMD

Revised reporting date for phase III study of Corlux

Corcept closes enrollment in Corlux study in Alzheimer's patients

Low dose oral interferon alpha studied for bone marrow proliferative disorders

ADX-10059 enters phase I studies for anxiety disorders and migraine

VT-111 begins phase II trial for acute coronary syndromes

Actilon begins phase Ib study for chronic HCV

AT-1001 enters phase I testing for celiac disease

Tissue distribution of SVT-40776 indicates a good safety profile

Pentacel BLA accepted for filing

UR-1505 modulates T cell proliferation and cytokine production

New data presented on GSK-3 dual inhibitor that demonstrates bone formation

Lck inhibition prevents acute rejection of heart transplants

Regeneron updates progress of key programs

Exatecan mesilate investigated in metastatic gastric cancer

Approvable letter for iPlex

Positive opinions in Europe for Combigan

Studies reveal temsirolimus activity in different cancers

Stiefel licenses albaconazole from Uriach

Recent patents report novel treatments for obesity

DOV-216303 shows promise in the management of major depression

Phase I data on arsenic trioxide plus dacarbazine in metastatic melanoma

Canvaxin improves survival of patients with high-risk melanoma

New thrombin inhibitors claimed in AstraZeneca patent

BAY-43-9006 shows antitumor activity in metastatic melanoma

Novel agents for diabetes and related complications reported in recent patent literature

Popular Stories

Today's news in brief
BioWorld
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...